Secondary Logo

Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers

Kim, Connie J.a,b; Rousseau, Rodneyb; Huibner, Sanjab; Kovacs, Colinc; Benko, Erikac; Shahabi, Kamnooshb; Kandel, Gabord; Ostrowski, Marioa,d; Kaul, Ruperta,b

doi: 10.1097/QAD.0000000000001515
BASIC SCIENCE: CONCISE COMMUNICATION
Free
SDC

Objective: Standard antiretroviral therapy (ART) is slow to reverse gut mucosal immune defects that cause persistent inflammation and immune activation. We examined whether intensifying early-administered ART through the addition of maraviroc and raltegravir would accelerate their resolution.

Design: ART-naïve men with early HIV infection were randomized in a double-blind manner to receive ART (emtricitabine/tenofovir disoproxil fumarate + lopinavir/ritonavir), together with either combined placebo or raltegravir + maraviroc, for 48 weeks. In a predefined substudy, paired blood and sigmoid biopsies were collected at baseline and week 48. Mucosal CD4+ T-cell immune subsets (Th1, Th17, and Th22 cells), CD8+ T-cell immune activation, and soluble blood markers of inflammation (IL-6, IL-17, macrophage inflammatory protein-1b, soluble CD14, and IL-10) and coagulation (D-dimer) were measured.

Results: A total of 22 participants were enrolled, a median of 4 months after HIV acquisition. At baseline, there was substantial systemic and mucosal immune activation, and gut CD4+ T-cell numbers, Th22 cell numbers, and Th17 cell function were reduced compared with controls. Early ART restored gut Th22 numbers, improved but did not restore overall CD4+ numbers, and had no impact on Th17 function. Plasma levels of soluble CD14 and D-dimer normalized, whereas other inflammatory cytokines were reduced but not normalized. ART intensification had no impact on any blood or gut immune parameters.

Conclusion: Early HIV infection causes substantial mucosal and systemic immune activation, and gut CD4+ T-cell dysfunction. One year of ART improved but did not normalize most parameters, regardless of intensification with raltegravir and maraviroc, and did not restore mucosal Th17 function.

Supplemental Digital Content is available in the text

aUniversity Health Network

bDepartments of Medicine and Immunology, University of Toronto

cMaple Leaf Medical Clinic

dSt. Michael's Hospital, Toronto, Ontario, Canada.

Correspondence to Connie J. Kim, Departments of Medicine and Immunology, University of Toronto, Medical Sciences Building, Rm 6356, Toronto, ON, Canada M5S 1A8. Tel: +1 416 946 7054; fax: +1 416 978 8765; e-mail: kim.connie@gmail.com

Received 2 March, 2017

Revised 10 April, 2017

Accepted 18 April, 2017

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).

Back to Top | Article Outline

Introduction

People living with HIV demonstrate increased mortality and comorbidity, especially when antiretroviral therapy (ART) is delayed [1,2]. Persistent systemic inflammation despite ART may contribute to these adverse health outcomes [3,4]; immune alterations include blood CD8+ T-cell immune activation [5] and elevated soluble markers of coagulation and inflammation [4,6,7]. Therefore, clinical interventions to reduce persistent inflammation may improve the health of ART-treated individuals.

One major driver of systemic inflammation is the translocation of gut luminal microbes into the bloodstream [8], resulting from a combination of mucosal immunodeficiency [9], epithelial barrier dysfunction [10], and dysbiosis of the gut microbiota [11]. Although standard ART generally reconstitutes peripheral blood immune cells, gut mucosal restoration is often delayed and incomplete [9]. Mucosal CD4+ T-cell subsets, including regulatory T cells (Tregs), Th17, Th1, and Th22 cells are important in host mucosal defense but are rapidly altered following HIV infection [12–15]. Th22 cells normally maintain and repair the gut by increasing enterocyte survival [13], whereas Th17 cells play a role in tissue repair and defense against extracellular bacteria and fungi [16], but both are reduced in number and/or function during untreated and early treated HIV infection [12,13,17].

Rapid initiation of ART reduces AIDS and non-AIDS-related morbidity [18] and levels of inflammatory cytokines [4,19]. Although less is known about how the timing of ART initiation impacts gut immunology, treatment initiated in the earliest stages of acute HIV infection preserved gut immune function and reversed immune activation [20]. Moreover, individuals with prolonged continuous viral suppression on ART (>6 years) demonstrated complete restoration of gut CD4+ T cells and of Th17 numbers and function [12,17,21]. However, in clinical practice, it is unusual to diagnose and start ART during acute HIV infection, and the slow gut immune restoration when ART is initiated later is discouraging.

We hypothesized that newer antiviral agents with improved drug penetration into gut tissues, specifically maraviroc [chemokine receptor type 5 (CCR5) inhibitor] and raltegravir (integrase inhibitor), might accelerate gut T-cell homeostasis [22]. We therefore randomized individuals who were starting ART early after HIV acquisition to receive either a standard protease inhibitor-based ART regimen, or a regimen intensified through the addition of raltegravir and maraviroc.

Back to Top | Article Outline

Methods

Study design

This protocol was a predefined substudy nested within a larger prospective, randomized, double-blinded, placebo-controlled trial (NCT01154763) [23], in which men recently infected by a CCR5-tropic HIV strain were randomized 1 : 1 to receive either emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg QD + lopinavir 400 mg/ritonavir 100 mg BID (standard regimen; sART) or to receive the standard regimen and raltegravir 400 mg BID and maraviroc 150 mg BID (intensified regimen; iART). Specifically, a subset of participants from that trial (n = 22) consented to provide paired sigmoid biopsies and peripheral blood at baseline and week 48.

Back to Top | Article Outline

Participants

Participants with documented early HIV infection (≤7 months) and HIV-uninfected controls from the same community were enrolled; details regarding sexual practices were not collected (Maple Leaf Medical Clinic, Toronto, Ontario, Canada). A multiassay algorithm on baseline sera was used to estimate timing of HIV infection [23], as previously described [24]. The research ethics boards at University of Toronto and St Michael's Hospital approved the study, and all participants provided written informed consent.

Back to Top | Article Outline

Immune cell isolation from blood and gut

Peripheral blood mononuclear cells were isolated by Ficoll–Hypaque density centrifugation. Sigmoid biopsies were collected 25–30 cm from the anal verge as previously described [12] and immediately placed into RPMI solution (RPMI-1640 media containing 100 U/ml penicillin, 100 μg/ml streptomycin, and 1× GlutaMAX-1; Invitrogen, Carlsbad, California, USA). Gut mononuclear cells were extracted by two serial collagenase type II digestions at 0.5 and 1.0 mg/ml for 30 min each on a shaking heated block (Clostridiopeptidase A; Sigma-Aldrich, St Louis, Missouri, USA).

Back to Top | Article Outline

Flow cytometry immune studies

Mononuclear cells were stained immediately after isolation or stimulated in RPMI solution containing 10% fetal bovine serum (FBS) with phorbol 12-myristate 13-acetate (1 ng/ml) and ionomycin (1 μmol/ml) for 6 h at 37 °C, and with Brefeldin A for the final 5 h (1 μmol/ml). Cells were washed in 1% FBS-1× PBS, permeabilized, stained for 30 min with fluorochrome-labeled mAbs and a viability dye and fixed. Antibodies included anti-CD3, CD4+, CD8+, human leukocyte antigen – antigen D related (HLA-DR), CD38, IL-17a, IL-22, IFNγ, and tumor necrosis factor. Cells were acquired on a FACSCanto II or LSR II (BD Biosciences, La Jolla, California, USA). Data analysis was performed using Flow Jo software v9.8 (Treestar, Ashland, Oregon, USA) and SPICE v5.3 (NIAID/NIH, Rockville, Maryland, USA) for polyfunctionality analysis. Flow cytometric gating was determined using media control and/or all fluorescence minus one controls, and values for functional cell subsets were background-corrected.

Back to Top | Article Outline

Blood biomarker measurement

Assays were performed in duplicate according to the manufacturers’ protocols. Plasma assays used commercially available ELISA kits to quantify soluble CD14 (sCD14) (R&D), D-dimer (Sekisui Diagnostics, Lexington, Massachussets, USA) and LPS (Lonza Cambrex, Charles City, Iowa, USA), and a custom-designed multiplex ELISA for IL-6, IL-10, IL-17, macrophage inflammatory protein (MIP)-1b, and tumor necrosis factor (Meso Scale Discovery, Rockville, Maryland, USA).

Back to Top | Article Outline

Statistical analysis

Mann–Whitney and Wilcoxon tests were performed using Prism 6 (GraphPad, La Jolla, California, USA) and SPICE software (v5.3). P < 0.05 was considered statistically significant.

Back to Top | Article Outline

Results

Study participant blood characteristics

Participants in the two groups were similar in age (P = 0.557) and infected with HIV, a median of 4 months ago (P = 0.809; Table 1). The sART and iART arms did not differ in blood CD4+ cell count, CD4+ : CD8+ ratio, CD8+ T-cell immune activation (HLA-DR + CD38 + coexpression), or soluble markers of inflammation/microbial translocation at baseline and demonstrated a similar change in all parameters at week 48 (Table 1). Time to HIV viral suppression following ART initiation was also similar (sART, 2.0 vs. iART 1.5 months; P = 0.753).

Table 1

Table 1

Back to Top | Article Outline

Overall impact of early antiretroviral therapy on soluble and cellular immune parameters in blood

As ART intensification did not impact blood immune parameters, data from the two groups were pooled to assess the overall impact of early ART initiation. At baseline, blood CD8+ T-cell activation was elevated almost 10-fold compared with HIV-uninfected controls (20.6 vs. 2.9%; P < 0.001) and decreased but remained higher than uninfected controls by 48 weeks (5.95%; P = 0.031; Supplemental Fig. 1a, http://links.lww.com/QAD/B95). Neither the frequency nor function of blood Th17 cells differed between participants with early HIV infection and HIV-uninfected controls, or between sART and iART groups at baseline or week 48 (P > 0.05 for all). Plasma biomarkers of inflammation and indirect marker of microbial translocation (sCD14) were also increased at baseline, but only D-dimer normalized after 48 weeks of ART (P = 0.226); IL-10, IL-17, and MIP-1b decreased on ART but remained significantly elevated, whereas IL-6, IL-17, and sCD14 levels did not change on ART (Supplemental Fig. 1b–g, http://links.lww.com/QAD/B95). Plasma LPS levels did not differ from uninfected controls at baseline or week 48 (P > 0.05; data not shown). Significantly, tumor necrosis factor levels were also similar at baseline to HIV-uninfected controls but significantly increased after ART (Supplemental Fig. 1h, http://links.lww.com/QAD/B95).

Back to Top | Article Outline

No impact of antiretroviral therapy intensification on gut immunology

In the gut, all measured immune variables were comparable at baseline between the two groups (Fig. 1; P > 0.05 for all), and intensification did not alter the change after 48 weeks in CD8+ T-cell immune activation, % CD4+ T cells, CD4+ : CD8+ ratio, %Th1, %Th22, or %Th17 cells (P > 0.05).

Fig. 1

Fig. 1

Back to Top | Article Outline

Impact of early antiretroviral therapy on gut immunology

As ART intensification did not alter gut immune restoration, data were again pooled from the two arms to characterize the impact of early ART initiation. At baseline, gut CD8+ T-cell immune activation was substantially elevated compared with uninfected controls, with a reduced CD4+ T-cell proportion and a CD4+ : CD8+ ratio that improved but did not normalize on ART (Fig. 1a–c). Frequencies of CD4+ sigmoid Th1 cells (IFNγ+) and regulatory T cells (Foxp3+CD25+) were similar to HIV-uninfected controls, both before and after ART (P > 0.05), whereas Th22 cell frequencies (IL-22+IFNγ−IL17a−) were dramatically reduced at baseline, there was near-complete reconstitution after ART (Fig. 1d and e). Th17 cell frequencies (IL-17a+) were comparable with HIV-uninfected controls at baseline and week 48, but their capacity to produce cytokines was dramatically reduced, both before and after a year of ART (Fig. 1f and g).

Back to Top | Article Outline

Discussion

The predefined clinical substudy investigated the mucosal immune impact of ART initiated during early stages of HIV infection, and whether intensification of ART at this stage might provide superior blood and gut immune reconstitution. Intensification through the addition of maraviroc and raltegravir to standard ART did not provide any additional benefit in blood immune parameters after 48 weeks, as seen in prior studies in this and later stages of HIV infection [25–27], and nor did intensification improve gut immune parameters. Substantial increases in blood and gut immune activation were apparent in these early stages of untreated HIV and did not normalize after a year of ART; although most soluble blood inflammatory biomarkers decreased, some did not change (sCD14, LPS, IL-17, and IL-10), and tumor necrosis factor levels actually increased. Mucosal CD4+ T-cell proportions and the mucosal CD4+ : CD8+ ratio increased, and gut CD8+ T-cell activation decreased considerably on ART but did not normalize, whereas mucosal Th22 populations were completely restored. Mucosal Th17 cell proportions were not reduced prior to ART or after ART; however, their function was substantially reduced and did not improve with ART. Overall, substantial mucosal and systemic immune dysfunction was apparent during early HIV infection; this dysfunction was only partially corrected by ART, and intensification with maraviroc and raltegravir did not provide any additional benefit.

ART intensification with newer antivirals that demonstrate enhanced gut tissue penetration showed no systemic or mucosal immune benefit in this small substudy, or virologic benefit in our overall protocol [23]. A prior clinical trial showed that maraviroc had better drug distribution in the gut than efavirenz or raltegravir, and that duodenal concentrations were associated with nonsignificant trends to improved CD4+ : CD8+ ratio, CD8+ T-cell immune activation, and CD4+ frequency [22]. Despite a lack of overall benefit, we did not measure maraviroc levels in the gut and therefore cannot rule out that higher drug concentrations in the gut might better restore gut immune subsets and/or accelerate local virologic suppression.

Reversing HIV-associated mucosal immune damage remains a challenge. ART initiated in the earliest phases of HIV infection can prevent some aspects of immune gut damage [20], but even treatment started during Fiebig stages I-II failed to completely restore mucosal CD4+ T cells after 2 years [28]. In our study, 1 year of ART initiated 4 months after HIV infection did not normalize gut immune activation or overall mucosal CD4+ T-cell numbers. However, gut CD4+ T-cell immune subsets were affected by HIV to different degrees, and those affected were reconstituted at varying rates. In contrast with other groups who found Th17 depletion at Fiebig stage III or later [20] but in keeping with our own earlier findings [12]; whether this represents differences in participant demographics or other factors is unknown. Th22 cell number and Th17 function were dramatically reduced, but although the former had normalized completely by a year, Th17 function did not improve. The timing of numerical and functional reconstitution within each subset beyond 48 weeks or the reasons for this subset heterogeneity are unclear but will be interesting topics for future research. Given the limited ability of current screening practices to identify even early HIV-infected individuals, effective clinical strategies to accelerate gut immune reconstitution remain a research priority.

Back to Top | Article Outline

Acknowledgements

The current work was supported the Canadian Institutes of Health Research (CIHR; TMI-138656 and THA-11900) and an unrestricted research grant from Merck, and study medications were provided by Gilead, Abbvie, Merck, ViiV, Janssen, and Pfizer. We acknowledge salary support from the CIHR Canadian HIV Trials Network (CJK), the Ontario HIV Treatment Network (OHTN; MO), and the University of Toronto – OHTN Endowed Research Chair (RK). We would like to thank Dr. Tae-Wook Chun from the NIH for technical assistance and the study participants for their time, contribution, and effort.

Author contribution

Conceived and designed the trial: C.J.K., C.K., M.O., and R.K.

Performed experiments and acquired data: C.J.K., R.R., S.H., E.B., K.S., and G.K.

Analyzed and interpreted the data: C.J.K. and R.K.

Drafted the article: C.J.K. and R.K.

All authors read and approved the final draft of the article and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work will be appropriately investigated and resolved.

Back to Top | Article Outline

Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline

References

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293–299.
2. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F. ATHENA National Observational Cohort Study. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010; 24:1527–1535.
3. Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012; 9:139–147.
4. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
5. Hunt PW, Cao HL, Muzoora C, Ssewanyana I, Bennett J, Emenyonu N, et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS 2011; 25:2123–2131.
6. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780–790.
7. Leeansyah E, Malone DF, Anthony DD, Sandberg JK. Soluble biomarkers of HIV transmission, disease progression and comorbidities. Curr Opin HIV AIDS 2013; 8:117–124.
8. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365–1371.
9. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003; 77:11708–11717.
10. Nazli A, Chan O, Dobson-Belaire WN, Ouellet M, Tremblay MJ, Gray-Owen SD, et al. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog 2010; 6:e1000852.
11. Dillon SM, Lee EJ, Kotter CV, Austin GL, Dong Z, Hecht DK, et al. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol 2014; 7:983–994.
12. Kim CJ, McKinnon LR, Kovacs C, Kandel G, Huibner S, Chege D, et al. Mucosal Th17 cell function is altered during HIV infection and is an independent predictor of systemic immune activation. J Immunol 2013; 191:2164–2173.
13. Kim CJ, Nazli A, Rojas OL, Chege D, Alidina Z, Huibner S, et al. A role for mucosal IL-22 production and Th22 cells in HIV-associated mucosal immunopathogenesis. Mucosal Immunol 2012; 5:670–680.
14. Cecchinato V, Trindade CJ, Laurence A, Heraud JM, Brenchley JM, Ferrari MG, et al. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol 2008; 1:279–288.
15. Prendergast A, Prado JG, Kang YH, Chen F, Riddell LA, Luzzi G, et al. HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells. AIDS 2010; 24:491–502.
16. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008; 453:1051–1057.
17. Chege D, Sheth PM, Kain T, Kim CJ, Kovacs C, Loutfy M, et al. Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS 2011; 25:741–749.
18. El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283–2296.
19. Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi-Lepri A, et al. Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy. PLoS One 2016; 11:e0155100.
20. Schuetz A, Deleage C, Sereti I, Rerknimitr R, Phanuphak N, Phuang-Ngern Y, et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog 2014; 10:e1004543.
21. Sheth PM, Chege D, Shin LY, Huibner S, Yue FY, Loutfy M, et al. Immune reconstitution in the sigmoid colon after long-term HIV therapy. Mucosal Immunol 2008; 1:382–388.
22. Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Chun TW, Mann S, et al. Effects of combined CCR5/integrase inhibitors-based regimen on mucosal immunity in HIV-infected patients naive to antiretroviral therapy: a pilot randomized trial. PLoS Pathog 2016; 12:e1005381.
23. Ostrowski M, Benko E, Yue FY, Kim CJ, Huibner S, Lee T, et al. Intensifying antiretroviral therapy with raltegravir and maraviroc during early human immunodeficiency virus (HIV) infection does not accelerate HIV reservoir reduction. Open Forum Infect Dis 2015; 2:ofv138.
24. Laeyendecker O, Brookmeyer R, Cousins MM, Mullis CE, Konikoff J, Donnell D, et al. HIV incidence determination in the United States: a multiassay approach. J Infect Dis 2013; 207:232–239.
25. Markowitz M, Evering TH, Garmon D, Caskey M, La Mar M, Rodriguez K, et al. A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals. J Acquir Immune Defic Syndr 2014; 66:140–147.
26. Puertas MC, Massanella M, Llibre JM, Ballestero M, Buzon MJ, Ouchi D, et al. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. AIDS 2014; 28:325–334.
27. Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011; 203:960–968.
28. Deleage C, Schuetz A, Alvord WG, Johnston L, Hao XP, Morcock DR, et al. Impact of early cART in the gut during acute HIV infection. JCI Insight 2016; 1:e87065.
Keywords:

blood biomarkers; CD4+ immunology; CD4+ T cells; early HIV infection; early treatment; gut immunology; inflammation; intensified antiretroviral treatment; microbial translocation; mucosal immunology; randomized controlled trial

Supplemental Digital Content

Back to Top | Article Outline
Copyright © 2017 Wolters Kluwer Health, Inc.